-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, D5HPM3/I0OkLz/ohcb3TWgeHd7P/bUe+5weppQMrfxfSn/Yz2GebNUXRztT/5kXp l09Dpl5h5eZbQYSWlr50FQ== 0000950130-97-005279.txt : 19971126 0000950130-97-005279.hdr.sgml : 19971126 ACCESSION NUMBER: 0000950130-97-005279 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19971124 ITEM INFORMATION: FILED AS OF DATE: 19971125 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROBERTS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000853022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222429994 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 001-10432 FILM NUMBER: 97727676 BUSINESS ADDRESS: STREET 1: 4 INDUSTRIAL WAY WEST STREET 2: 4 INDUSTRIAL WAY W CITY: EATONTOWN STATE: NJ ZIP: 07755 BUSINESS PHONE: 7323891182 MAIL ADDRESS: STREET 1: 4 INDUSTRIAL WAY WEST STREET 2: 4 INDUSTRIAL WAY WEST CITY: EATONTOWN STATE: NJ ZIP: 07755 8-K 1 FORM 8-K FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 1997 ROBERTS PHARMACEUTICAL CORPORATION - -------------------------------------------------------------------------------- (exact name of registrant as specified in its charter New Jersey 1-1-432 22-2429994 - --------------- ----------- -------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification incorporation) Number) Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: 908-389-1182 Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Former name or former address, if changed from last report) -2- Item 5. Other Events ------------ Roberts Pharmaceutical Corporation announced today that its new drug Agrylin/TM/ (anagrelide hydrochloride) has successfully completed both clinical and labeling reviews by the Health Protection Branch (HPB) and the product is cleared for marketing in Canada. The Company's wholly owned subsidiary Roberts Pharmaceutical Canada will market Agrylin/TM/ in Canada. Roberts expects to launch the product in Canada in early January 1998. Agrylin/TM/, having been launched in the U.S. in March of this year is the first drug cleared for marketing by both the FDA and HPB for the treatment of essential thrombocythemia, a life threatening condition characterized by elevated blood platelet counts. Agrylin/TM/ is currently under review for approval in the European Union. The Company commented that Agrylin/TM/ is the first drug to emerge from their product pipeline with the potential for worldwide marketing. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROBERTS PHARMACEUTICAL CORPORATION ---------------------------------- (Registrant) Date: November 25, 1997 By: /s/ Anthony A. Rascio ------------------------------ Anthony A. Rascio Vice President -----END PRIVACY-ENHANCED MESSAGE-----